Carcinogenesis, Vol. 20, No. 3, 415-419,
March 1999
© 1999 Oxford University Press
Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugs
Unité 347 INSERM, 80 Rue du Général Leclerc, 94276 Le Kremlin Bicêtre, France
Abasic sites (AP sites) are generated in DNA either directly by DNA-damaging agents or by DNA glycosylases acting during base excision repair. These sites are repaired in human cells by the HAP1 protein, which, besides its AP-endonuclease activity, also possesses a redox function. To investigate the ability of HAP1 protein to modulate cell resistance to DNA-damaging agents, CHO cells were transfected with HAP1 cDNA, resulting in stable expression of the protein in the cell nuclei. The sensitivity of the transfected cells to the toxic effect of various agents, e.g. methylmethane sulfonate, bleomycin and H2O2, was not modified. However, the transfected cells became more sensitive to killing by mitomycin C, porfiromycin, daunorubicin and aziridinyl benzoquinone, drugs that are activated by reduction. To test whether the redox function of HAP1 protein was involved in this increased cytotoxicity, we have constructed a mutated HAP1 protein endowed with normal AP-endonuclease activity but deleted for redox function. When this mutated protein was expressed in the cells, elevated AP-endonuclease activity was measured, but sensitization to the lethal effects of compounds requiring bioreduction was no longer observed. These results suggest that HAP1 protein, besides its involvement in DNA repair, is able to activate bioreduction of alkylating drugs used in cancer chemotherapy.
Abbreviations: AP sites, apurinic/apyrimidinic sites; DTD, DT-diaphorase; DZQ, 3,6-diaziridinyl-1,4-benzoquinone; GSH, reduced glutathione; MMC, mitomycin C; MMS, methylmethane sulfonate; NAC, N-acetylcysteine.
1 To whom correpondence should be addressed Email: laval{at}kb.inserm.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Zhang, T. Mizumachi, J. Carcel-Trullols, L. Li, A. Naito, H. J. Spencer, P. M. Spring, B. R. Smoller, A. J. Watson, G. P. Margison, et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells Carcinogenesis, August 1, 2007; 28(8): 1629 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sossou, C. Flohr-Beckhaus, I. Schulz, F. Daboussi, B. Epe, and J. P. Radicella APE1 overexpression in XRCC1-deficient cells complements the defective repair of oxidative single strand breaks but increases genomic instability Nucleic Acids Res., January 12, 2005; 33(1): 298 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Freitas, D. H. Moore, H. Michael, and M. R. Kelley Studies of Apurinic/Apyrimidinic Endonuclease/ref-1 Expression in Epithelial Ovarian Cancer: Correlations with Tumor Progression and Platinum Resistance Clin. Cancer Res., October 15, 2003; 9(13): 4689 - 4694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Flaherty, M. M. Monick, and G. W. Hunninghake AP Endonucleases and the Many Functions of Ref-1 Am. J. Respir. Cell Mol. Biol., December 1, 2001; 25(6): 664 - 667. [Full Text] [PDF]
|
|
|
|
|
|
G. Frosina Counteracting spontaneous transformation via overexpression of rate-limiting DNA base excision repair enzymes Carcinogenesis, September 1, 2001; 22(9): 1335 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nilsen and H. E. Krokan Base excision repair in a network of defence and tolerance Carcinogenesis, July 1, 2001; 22(7): 987 - 998. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Kelley, L. Cheng, R. Foster, R. Tritt, J. Jiang, J. Broshears, and M. Koch Elevated and Altered Expression of the Multifunctional DNA Base Excision Repair and Redox Enzyme Ape1/ref-1 in Prostate Cancer Clin. Cancer Res., April 1, 2001; 7(4): 824 - 830. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. K. Hansen and M. R. Kelley Review of Mammalian DNA Repair and Translational Implications J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 1 - 9. [Abstract] [Full Text]
|
|